Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

617.00GBp
23 May 2018
Change (% chg)

1.00 (+0.16%)
Prev Close
616.00
Open
616.00
Day's High
621.50
Day's Low
609.00
Volume
731,937
Avg. Vol
769,661
52-wk High
784.00
52-wk Low
540.00

Chart for

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): £2,754.76
Shares Outstanding(Mil.): 386.36
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 82.78 30.95 32.75
EPS (TTM): 0.09 -- --
ROI: 3.10 14.84 14.38
ROE: 3.68 16.34 16.07

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

18 Jan 2018

Earnings vs. Estimates